Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity

Carla Giordano, Franzetti, Olga Cervone, Alessandra Dei Cas, Carla Rizzo, Mimma Rizzo, Fabrizio Querci, Gian Pio Sorice, Vera Frison, Leto, Giovanni Grossi, Federica D'Angelo, Gruden, Edoardo Duratorre, Carmela Vinci, Mannina, Antenucci, Giuseppe Capobianco, Giuseppe Saglietti, Massimiliano PetrelliMaria A. Rizzo, Giuseppe Felace, Maurizio Poli, Achiropita Pucci, Piro, Arena, Silvestre Cervone, Roberta Chianetta, Natali, Carlo Bossi, Silvia Morpurgo, Cristiano Chilelli, Indrieri, Giordano, Malagola, Patrizia Li Volsi, Lamacchia, Ioannis Karamouzis, Raffaella Buzzetti, Dotta, Rizzo, Fadini, Karamouzis, Natalino Simioni, Fattor, Dotta, Francesco Andreozzi, Gianluca Aimaretti, Frittitta, Ivana Zavaroni, Emanuela Orsi, Franco Cavalot, Susanna Morano, Giaccari, Antonino Di Benedetto, Enzo Bonora, Massimo Boemi, Giorgio Sesti, Angelo Avogaro, Francesco Dotta, Francesco Fattor, Annunziata Lapolla, Buzzetti, Leto, Solini, Riccardo Bonadonna, Massimo Cigolini, Anichini, Adriano Gatti, Consoli, Giuliana Cazzetta, Formoso, Zatti, Eleonora Devangelio

Risultato della ricerca: Articlepeer review

22 Citazioni (Scopus)


Background Randomized controlled trials (RCTs) in the field of diabetes have limitations inherent to the fact that design, setting, and patient characteristics may be poorly transferrable to clinical practice. Thus, evidence from studies using routinely accumulated clinical data are increasingly valued. Aims We herein describe rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes), a multicenter retrospective nationwide study conducted at 50 specialist outpatient clinics in Italy and promoted by the Italian Diabetes Society. Data synthesis The primary objective of the study is to describe the baseline clinical characteristics (particularly HbA1c) of patients initiated on dapagliflozin from marketing authorization approval to the end of 2016. Secondary and exploratory objectives will evaluate the changes in glycaemic and extraglycaemic efficacy parameters after initiation of dapagliflozin or after initiation of comparator glucose lowering medications (DPP-4 inhibitors, gliclazide extended release, and long-acting GLP-1 receptor agonists). An automated software will extract relevant data from the same electronic chart system at all centres, thereby minimizing data treatment and human intervention. Conclusion The study is expected to collect an enormous dataset of information on dapagliflozin- and comparator-using patients. After study completion, the Italian Diabetes Society will launch an open crowdsourcing call on the DARWIN-T2D database, challenging diabetes researchers to apply their ideas and approaches to address new unmet needs and knowledge gaps in diabetes. We believe this will move DARWIN-T2D to the next generation of real world studies.
Lingua originaleEnglish
pagine (da-a)1089-1097
Numero di pagine9
Stato di pubblicazionePublished - 2017

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2701???
  • ???subjectarea.asjc.2700.2712???
  • ???subjectarea.asjc.2900.2916???
  • ???subjectarea.asjc.2700.2705???


Entra nei temi di ricerca di 'Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity'. Insieme formano una fingerprint unica.

Cita questo